Evolution of Blast Crisis (BC) in Chronic Myeloid Leukemia (CML) in the Imatinib-Era: A Rare Event with High Proportions of Low Risk Patients and of Early Bc; Need for Rapid Detection. Results of the German CML Study IV

Abstract 3287 Poster Board III-1 Blast crisis (BC) in CML in the imatinib era is a rare event with 1–3% of newly diagnosed BC patients per year in the IRIS study, but prognosis, once BC has occurred, remains poor. Historical and recent studies with imatinib and second generation tyrosine kinase inhi...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2009-11, Vol.114 (22), p.3287-3287
Main Authors: Saussele, Susanne, Lauseker, Michael, Pfirrmann, Markus, Leitner, Armin, Pletsch, Nadine, Stegelmann, Frank, Ho, Anthony D, Schlimok, Günter, Lindemann, Albrecht, Beelen, Dietrich W, Gratwohl, Alois, Hänel, Mathias, Haferlach, Claudia, Schlegelberger, Brigitte, Müller, Martin C, Erben, Philipp, Schnittger, Susanne, Jung-Munkwitz, Susanne, Shazi, Samina, Hasford, Joerg, Hochhaus, Andreas, Hehlmann, Rüdiger, The German CML Study Group
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract 3287 Poster Board III-1 Blast crisis (BC) in CML in the imatinib era is a rare event with 1–3% of newly diagnosed BC patients per year in the IRIS study, but prognosis, once BC has occurred, remains poor. Historical and recent studies with imatinib and second generation tyrosine kinase inhibitors (TKI) reported a median survival time of 7–10 months and two year survival probabilities of
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V114.22.3287.3287